Equity Overview
Price & Market Data
Price: $1.35
Daily Change: +$0.03 / 2.22%
Range: $1.32 - $1.37
Market Cap: $85,443,664
Volume: 40,765
Performance Metrics
1 Week: 3.46%
1 Month: 1.89%
3 Months: -23.58%
6 Months: -29.40%
1 Year: -50.37%
YTD: 4.26%
Company Details
Employees: 15
Sector: Health technology
Industry: Biotechnology
Country: United States
Details
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the drug research and development to create new therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02), a galectin-3 inhibitor, which is in Phase 2b/3 clinical trial to prevent esophageal varices in patient with non-alcoholic steatohepatitis cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma. Galectin Therapeutics Inc. has a collaborative joint venture co-owned by SBH Sciences, Inc. with Galectin Sciences, LLC for the research and development of small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.